Shen Yudao, Szewczyk Magdalena M, Eram Mohammad S, Smil David, Kaniskan H Ümit, de Freitas Renato Ferreira, Senisterra Guillermo, Li Fengling, Schapira Matthieu, Brown Peter J, Arrowsmith Cheryl H, Barsyte-Lovejoy Dalia, Liu Jing, Vedadi Masoud, Jin Jian
Department of Pharmacological Sciences and Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Structural Genomics Consortium, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.
J Med Chem. 2016 Oct 13;59(19):9124-9139. doi: 10.1021/acs.jmedchem.6b01033. Epub 2016 Sep 15.
Well-characterized selective inhibitors of protein arginine methyltransferases (PRMTs) are invaluable chemical tools for testing biological and therapeutic hypotheses. Based on 4, a fragment-like inhibitor of type I PRMTs, we conducted structure-activity relationship (SAR) studies and explored three regions of this scaffold. The studies led to the discovery of a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6, 17 (MS049). As compared to 4, 17 displayed much improved potency for PRMT4 and PRMT6 in both biochemical and cellular assays. It was selective for PRMT4 and PRMT6 over other PRMTs and a broad range of other epigenetic modifiers and nonepigenetic targets. We also developed 46 (MS049N), which was inactive in biochemical and cellular assays, as a negative control for chemical biology studies. Considering possible overlapping substrate specificity of PRMTs, 17 and 46 are valuable chemical tools for dissecting specific biological functions and dysregulation of PRMT4 and PRMT6 in health and disease.
特征明确的蛋白质精氨酸甲基转移酶(PRMTs)选择性抑制剂是用于检验生物学和治疗假说的宝贵化学工具。基于I型PRMTs的片段样抑制剂4,我们进行了构效关系(SAR)研究并探索了该支架的三个区域。这些研究导致发现了一种有效的、选择性的且具有细胞活性的PRMT4和PRMT6双重抑制剂17(MS049)。与4相比,17在生化和细胞试验中对PRMT4和PRMT6显示出显著提高的效力。它对PRMT4和PRMT6具有选择性,相对于其他PRMTs以及广泛的其他表观遗传修饰剂和非表观遗传靶点而言。我们还开发了在生化和细胞试验中无活性的46(MS049N),作为化学生物学研究的阴性对照。考虑到PRMTs可能存在的重叠底物特异性,17和46是用于剖析PRMT4和PRMT6在健康和疾病中的特定生物学功能及失调情况的宝贵化学工具。